
Michelin Guide expands to Philadelphia region
Philadelphia is a newly minted Michelin city.
Why it matters: The Michelin Guide is considered by some the gold standard of dining, a signal to the world that a city's restaurant scene has arrived.
Driving the news: The Philly region will be included in the Michelin Guide Northeast Cities edition alongside Boston, the only other freshman member.
The Philadelphia Convention and Visitors Bureau revealed its partnership with France-based Michelin on Monday.
Zoom out: Philly and Boston join the ranks of Chicago, New York City and D.C., which have been included in the guide for years.
How it works: The company is best known for issuing its coveted stars, which range from one to three.
Anonymous inspectors visit local restaurants, unannounced, to determine which deserve the accolade.
Restaurants that receive stars are often lauded as among the best in the world.
Flashback: In 2023, Michelin added Philly to its Green Guides, which highlight attractions, restaurants and hotels.
The intrigue: Bringing the pay-to-play Michelin Guide to town typically comes with a heavy price tag.
Visitors Bureau spokesperson Robin Bloom declined to reveal how much its partnership with Michelin costs, telling Axios the terms of the agreement are not public.
But state and local tourism boards in Miami, Tampa and Orlando, Florida, agreed in 2022 to shell out $1.5 million to Michelin over three years to get in the guide.
Atlanta is paying out $1 million, while Texas and five of its metros landed a guide for $900,000.
Meanwhile, some areas have declined to participate due to costs, like Virginia.
The big picture: Philly's restaurants and chefs have been in a league of their own in recent years — winning national recognition, big awards, opening hip spots and setting the standard for outstanding dining.
"Our chefs, restaurateurs, and hospitality professionals have been steadily building our city into an internationally acclaimed foodie destination," Gregg Caren, president and CEO of the Philly visitors bureau, said in a statement.
What's next: Philly tourism and elected officials, as well as Gov. Josh Shapiro, will join Gwendal Poullennec, international director of the Michelin Guide, Tuesday at the Barnes Foundation for a news conference about the partnership.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to 48 months. This shelf-life extension applies to the 50mg tablet strength of MASIVET® currently available in the EU. MASIVET® is currently approved for the treatment of non-resectable dog mast cell tumours (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor. It is marketed by AB Science and currently available in all EU countries. This extension of the shelf life gives patients, caregivers, and AB Science more flexibility to adjust inventory levels to current and future demand while reducing the risk of product expiration. At the same time, it ensures the continuity of current and future therapies and continues to enable veterinarians to provide their patients with the best available treatment. About AB ScienceFounded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Forward-looking Statements - AB ScienceThis press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations. For additional information, please contact: AB Science Financial Communication & Media Relations investors@ Attachment Masivet Shelf Life VENG VFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Renault may set up drone production in Ukraine
Bloomberg has reported that French car manufacturer Renault SA has held talks with the French Ministry of Defence regarding the production of drones in Ukraine. Source: Bloomberg Details: Bloomberg stressed that discussions took place, but no decision has been made at this stage, as the company is awaiting further details from the ministry. Prior to this, France Info reported that Renault would be working with a small company to set up production lines tens or hundreds of kilometres from the line of contact. According to the report, the drones could be used by Ukraine and the French army. The French Ministry of Defence declined to comment on this information. On 6 June, Defence Minister Sébastien Lecornu said that a major French car manufacturer would join forces with a small French defence company to equip production lines in Ukraine for the manufacture of drones. However, he did not name the car manufacturer. Background: On 5 June, Ukrainian and French defence ministers discussed possibilities for joint weapons production for the needs of Ukraine's defence forces during a meeting in Brussels. Ukraine and its partner countries decided to establish a mechanism for defence production, according to an agreement reached at the 28th meeting of the Ukraine Defence Contact Group (also known as the Ramstein Format) held on 4 June at NATO headquarters. Support Ukrainska Pravda on Patreon!
Yahoo
an hour ago
- Yahoo
Elis: Disclosure of trading in own shares occured from June 2 to June 6, 2025
Disclosure of trading in own shares occurred from June 2 to June 6, 2025 Saint-Cloud, June 9, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 2 to June 6, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code) ELIS SA 969500UX71LCE8MAY492 06/02/2025 FR0012435121 18,598 23.8024 XPAR ELIS SA 969500UX71LCE8MAY492 06/02/2025 FR0012435121 17,104 23.7620 DXE ELIS SA 969500UX71LCE8MAY492 06/03/2025 FR0012435121 51,714 23.4968 XPAR ELIS SA 969500UX71LCE8MAY492 06/03/2025 FR0012435121 6,151 23.4011 DXE ELIS SA 969500UX71LCE8MAY492 06/03/2025 FR0012435121 819 23.3894 TQE ELIS SA 969500UX71LCE8MAY492 06/03/2025 FR0012435121 716 23.3504 AQE ELIS SA 969500UX71LCE8MAY492 06/04/2025 FR0012435121 29,492 23.5757 XPAR ELIS SA 969500UX71LCE8MAY492 06/04/2025 FR0012435121 19,680 23.5711 DXE ELIS SA 969500UX71LCE8MAY492 06/05/2025 FR0012435121 23,990 23.4805 XPAR ELIS SA 969500UX71LCE8MAY492 06/05/2025 FR0012435121 6,119 23.4500 DXE ELIS SA 969500UX71LCE8MAY492 06/06/2025 FR0012435121 18,131 23.5994 XPAR ELIS SA 969500UX71LCE8MAY492 06/06/2025 FR0012435121 7,032 23.5599 DXE Total 199,546 23.5713 The purpose of the own shares purchase operations is (i) to cover maturing performance share plans and to allocate free shares to employees as part of the contribution to the Elis for All 2025 international employee shareholding plan, and (ii) to be cancelled in accordance with the 26th resolution of the Combined General Meeting of May 22, 2025. Contacts Nicolas BuronDirector of Investor Relations, Financing & TreasuryPhone: + 33 (0)1 75 49 98 30 - Charline LefaucheuxInvestor Relations Phone: + 33 (0)1 75 49 98 15 - Attachment Elis - Disclosure of trading in own shares occured from June 2 to June 6, 2025